Clinical Trial Update: Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN [Phase 1]

View source ↗

Summary

Phase 1 safety, tolerability, and pharmacokinetics study of CNTX-6016 in healthy subjects and patients with Painful Diabetic Neuropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Painful Diabetic Neuropathy

Drugs mentioned

• CNTX-6016

Snippet

Sponsor: Centrexion Therapeutics | Conditions: Painful Diabetic Neuropathy | Phase 1 | Status: COMPLETED